



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Armisarte

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
PSUSA/2330/202402	Periodic Safety Update EU Single assessment - pemetrexed	17/10/2024	12/12/2024	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for PSUSA/2330/202402.
N/0033	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	16/10/2023	10/05/2024	Labelling and PL	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



IG/1612	A.1 - Administrative change - Change in the name and/or address of the MAH	31/05/2023	11/08/2023	SmPC, Labelling and PL	
II/0030/G	This was an application for a group of variations. B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	23/03/2023	n/a		
IB/0031	B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation	18/01/2023	11/08/2023	SmPC, Labelling and PL	
IB/0029	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by	24/08/2022	11/08/2023	SmPC, Annex II and PL	

	the MAH				
PSUSA/2330/ 202102	Periodic Safety Update EU Single assessment - pemetrexed	30/09/2021	n/a		PRAC Recommendation - maintenance
IB/0027	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	03/08/2021	01/07/2022	SmPC, Labelling and PL	
IAIN/0028	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	02/08/2021	n/a		
IB/0024	B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation	29/06/2021	01/07/2022	SmPC, Labelling and PL	To include the dilution of Pemetrexed 25 mg/mL concentrate for solution for infusion in 0.9% sodium chloride to maintain the dilution stable for 24 hours at 25oC and 7 days at 2oC - 8oC.
IA/0026	B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information	08/06/2021	n/a		
IAIN/0023	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	22/04/2021	n/a		
R/0022	Renewal of the marketing authorisation.	25/06/2020	13/08/2020	SmPC, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Armisarte in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.

IB/0021	B.II.f.1.a.3 - Stability of FP - Reduction of the shelf life of the finished product - After dilution or reconstitution	26/03/2020	13/08/2020	SmPC and PL	
IA/0020	B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	17/03/2020	n/a		
PSUSA/2330/201802	Periodic Safety Update EU Single assessment - pemetrexed	18/10/2018	15/01/2019	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2330/201802.
IB/0019	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	18/12/2018	n/a		
II/0017/G	This was an application for a group of variations. B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	13/09/2018	n/a		
IAIN/0016	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	10/04/2018	15/01/2019	SmPC and PL	

IB/0014	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	10/10/2017	25/05/2018	SmPC, Labelling and PL	
IA/0015	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	28/09/2017	n/a		
IAIN/0013	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	28/09/2017	25/05/2018	Annex II and PL	
II/0008/G	This was an application for a group of variations. B.II.a.3.b.2 - Changes in the composition (excipients) of the finished product - Other excipients - Qualitative or quantitative changes in one or more excipients that may have a significant impact on the safety, quality or efficacy of the product B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products	18/05/2017	25/05/2018	SmPC, Labelling and PL	

IA/0011	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	05/04/2017	n/a		
IB/0009/G	This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products	25/01/2017	n/a		
IB/0007	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	05/01/2017	n/a		
IB/0006/G	This was an application for a group of variations. B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/immunological medicinal products B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change	21/09/2016	n/a		

	in the manufacturing process B.II.b.4.z - Change in the batch size (including batch size ranges) of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information				
N/0005	Update of the package leaflet with revised contact details of the local representatives for Belgium, the Netherlands and Portugal. In addition, the MAH took the opportunity to make linguistic corrections in the Danish, German, Greek, Finnish, Hungarian, Icelandic, Italian, Latvian, Maltese, Dutch, Norwegian, Portuguese and Swedish labelling and package leaflets in line with the EN text. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	20/06/2016	16/02/2017	PL	
IB/0003	B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)	11/03/2016	16/02/2017	SmPC and PL	

IB/0002	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	19/02/2016	16/02/2017	SmPC and PL	
IAIN/0001	A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs	10/02/2016	16/02/2017	SmPC, Labelling and PL	